First-line systemic therapy includes: (1) anti–programmed cell death protein 1 (PD-1) monotherapy with pembrolizumab or nivolumab; (2) nivolumab/ipilimumab; and (3) a combination of dabrafenib plus trametinib, vemurafenib plus cobimetinib, or encorafenib plus binimetinib if the tumor contains a BRAF V600–activating mutation (19). The gene discussed is PDCD1; the disease is neoplasm.